This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After a long, challenging period for CNS R&D – marked by late-stage clinical failures, mass layoffs, and limited early-stage

The equity markets have softened tremendously in recent weeks and the NASDAQ Biotech Index has swooned to levels last held in late 2014, in line with other equity indices like the S&P500.  Triggered by significant and negative macro forces, this

This blog was written by Bill Marshall, CEO of MiRagen Therapeutics in Boulder, CO, as part of the “From The Trenches” feature of LifeSciVC. Dictionary.com defines “outlier” as: (1) something that lies outside the main body or group that it

2015 was the biggest year ever for venture capital funding into the biotech sector. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $7.4B was invested during the year.  Lots

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. The wifi is predictably not working on my flight back from the JP Morgan Healthcare Conference (#JPM16), allowing me the

It’s that time of the year again.  As part of the annual pilgrimage, acolytes of the healthcare investment community are about to descend upon the Union Square area of San Francisco. As part of the ritual of the 34th Annual

The past five years have been the greatest bull run in the history of the biotech industry. Stock market outperformance, significant fundraising levels both private and public, more IPOs in this window than ever before, and huge volumes of M&A.

We’re excited to announce two new collaborations today from our neuroscience portfolio – Quartet with Merck (here) and Rodin with Biogen (here) – to advance their programs into early clinical development.  These are both young companies that we helped create

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I stumbled into a bit of a mess a few weeks ago. It was with the best of intentions, of course.

As 2015 comes to a conclusion, it’s a good time reflect on the year’s progress – celebrating the wins, thinking through the losses, and learning from both. One specific reflection of late regards this blog: I’ve looked back at the

This year I celebrated my 10-year work anniversary with Atlas.  Hard to believe how fast a decade flies by, and this milestone triggered some reflections on how times have changed in biotech and the early stage venture business. As we

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is that time of the year again when we start to get ready for the New Year.  It is